title: Editorial: Cutting edge in systemic lupus erythematosus.
authors.affiliation: Louise Coote Lupus Unit, Guys and St Thomas' Hospitals, London, UK. David.DCruz@gstt.nhs.uk.
authors.forename: David P
authors.initials: DP
authors.lastname: D'Cruz
authors.affiliation: Interdisciplinary Center for Clinical Trials (IZKS), University Medical Center Mainz, Mainz, Germany.|Division of Immunogenetics, Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Annegret
authors.initials: A
authors.lastname: Kuhn
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000276:immunology*; D053264:B-Cell Activating Factor / Q000276:immunology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia; D007108:Immune Tolerance; D007167:Immunotherapy / Q000379:methods*; D007239:Infections / Q000150:complications / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D011247:Pregnancy; D011248:Pregnancy Complications; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014807:Vitamin D
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; D014807:Vitamin D; C511911:belimumab